报价延迟最少15分钟:2026/09/18 13:40 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.26/-2.36
|
|
企业价值
550.56M
|
| 资产负债 |
|
每股账面净值
8.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
262.60M
|
|
每股收益
2.44
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases. |
